Efficacy of ranolazine in complex treatment of chronic coronary syndrome, chronic obstructive pulmonary disease and obese patients

February 3, 2022
722
Resume

Aim: to study the effectiveness of ranolazine in complex therapy in chronic coronary syndrome, chronic obstructive pulmonary disease and obese patients.

Object and methods of the study. Participants (n=30) were evenly divided into two groups: 1st (control), in which patients received standard therapy, and 2nd (main), in which patients received ranolazine at a dose of 500 mg 2 times a day for 1 month additional to complex therapy. The control group consisted of 20 healthy individuals.

Results. After treatment, the level of total cholesterol and atherogenic index was lower by 8.6% (p<0.05) and by 14.5% (p<0.05) in the main group compared to control. It was found a decrease by 5.9% (p<0.05) of NT-proBNP level, an increase by 21.6% (p<0.05) the content of stable metabolites of nitric oxide (NO), by 32.6% (p<0.05) NO3, a decrease by 3.6% (p<0.05) the level of endothelin-1 in the second patients’ group.

Conclusion. The use of ranolazine in complex therapy improves the plasma lipid spectrum (decrease total cholesterol and atherogenic index levels), endothelial function (increase the content of stable metabolites NO, NO3, decrease endothelin-1), and reduces NT-proBNP in chronic coronary syndrome, chronic obstructive pulmonary disease, and obese patients.

References

  • 1. Васина Л.В., Петрищев Н.Н., Власов Т.Д. (2017) Эндотелиальная дисфункция и ее основные маркеры. Регионарн. кровообр. и микроцирк., 16(1): 4–15. DOI: 10.24884/1682-6655-2017-16-1-4-15.
  • 2. Fesenko O., Bogatska K. (2018) Safety of nebivolol and bisoprolol in patients (pts) with COPD and stable angina. Eur. Respir. J., 52(suppl. 62): PA738. DOI: 10.1183/13993003.congress-2018.
  • 3. Suissa S., Dell’Aniello S., Ernst P. (2017) Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur. Respir. J., 49: 1602245. DOI: 10.1183/13993003.02245-2016.
  • 4. Knuuti J., Wijns W., Saraste A. et al. (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J., 41(3): 407–477. DOI: 10.1093/eurheartj/ehz425.
  • 5. Дмитриева И.С., Кравченко Е.В. (2017) Лекарственное средство ранолазин в терапии стабильной стенокардии. Кардиология в Беларуси, 9(4): 719–733.
  • 6. Щетинин П.П. (2015) Роль метаболической кардиопротекции в фармакотерапии ишемической болезни сердца. Акт. пробл. гуманит. ест. наук, 8(2): 125–129.
  • 7. Шуба Н.М., Кир’яченко С.П., Воронова Т.Д. та ін. (2017) Визначення ефективності ранолазину та його вплив на функцію клітин у хворих з ішемічною хворобою серця. Ліки України, 7(213): 53–57.
  • 8. Tuxunguli T., Aierken A., Xie X. et al. (2014) Association study of plasma NT-proBNP levels and severity of acute coronary syndrome. Genet. Mol. Res., 13(3): 5754–5757. DOI: 10.4238/2014.
  • 9. Labaki W.W., Xia M., Murray S. et al. (2018) NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. Respir. Med., 140: 87–93. DOI: 10.1016/j.rmed.2018.06.005.
  • 10. Rehberger-Likozar A., Šebeštjen M. (2015) Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease. Coron. Artery. Dis., 26(8): 651–656. DOI: 10.1097/MCA.0000000000000272.